New Antithrombotic Drugs*: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)*

    loading  Checking for direct PDF access through Ovid

Abstract

This chapter focuses on new antithrombotic drugs that are in phase II or III clinical testing. Development of these new agents was prompted by limitations of existing antiplatelet, anticoagulant, or fibrinolytic drugs. Addressing these unmet needs, this chapter (1) outlines the rationale for development of new antithrombotic agents, (2) describes the new antiplatelet, anticoagulant, and fibrinolytic drugs, and (3) provides clinical perspectives on the opportunities and challenges faced by these novel agents.

Related Topics

    loading  Loading Related Articles